Analysis of Short-term (Operating) Activity Ratios
Quarterly Data
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
DexCom Inc., short-term (operating) activity ratios (quarterly data)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
The analysis of the financial ratios over the given periods reveals several notable trends in operational efficiency and working capital management.
- Inventory Turnover
- The inventory turnover ratio experienced a decline from early 2019 through the end of 2021, dropping from a high of over 4 in 2019 to around 2 by late 2021. This indicates a slower rate of inventory sales or turnover over this period, suggesting potential challenges in inventory management or reduced sales velocity. However, starting from early 2022, there was a recovery in the inventory turnover ratio, rising back to over 3 at times in 2022, before a decline again to around 2.5 by the third quarter of 2023.
- Receivables Turnover
- This ratio showed relative stability overall, fluctuating between approximately 4 and 6 times throughout the periods. Notably, there was a slight downward trend after mid-2019, with values declining from around 5.75 to approximately 4 by 2023, indicating a marginal lengthening of the collection period. This suggests that receivables were being collected more slowly in recent years compared to 2019.
- Working Capital Turnover
- The working capital turnover ratio was relatively low in 2019 and early 2020, fluctuating around 0.7 to 0.9, indicating modest efficiency in generating sales from working capital. A decline was observed mid-2020, dropping to as low as 0.65, suggesting less effective use of working capital. From early 2021 onward, a positive trend emerged with a sharp increase peaking at 1.59 in early 2023, reflecting improved efficiency in managing working capital to drive revenue generation. This improvement, however, subsided somewhat in mid-2023.
- Average Inventory Processing Period
- The average number of days to process inventory increased steadily from 2019 through the end of 2021, rising from under 90 days to as many as 180 days, which corroborates the reduced inventory turnover ratio. The period then decreased substantially during 2022, dropping to about 109 days by year-end, showing a faster inventory movement. There was another increase in the first three quarters of 2023, climbing back near 148 days, indicating some easing in inventory management efficiency.
- Average Receivable Collection Period
- This metric also revealed a gradual lengthening of collection days over the observed periods. Initially consistent at around 65 days in 2019, it fluctuated but increased to as many as 89 days by early 2023. The upward trend points towards a slower collection of receivables, which may impact cash flows and working capital availability.
- Operating Cycle
- The operating cycle, representing the average time between inventory acquisition and cash collection from sales, lengthened significantly over time. From around 150-160 days in 2019 and 2020, it extended beyond 200 days from 2021 onward, peaking above 260 days at times in late 2021 and remaining elevated through 2023. This prolonged cycle indicates that the combined effect of slower inventory processing and extended receivables collection has increased the time required to convert resources into cash.
Overall, the data depicts a period of operational challenges marked by a slowdown in both inventory turnover and receivables collection, negatively affecting the operating cycle duration. Improvement in working capital turnover observed in 2021–2023 suggests efforts towards more efficient use of working capital, but the prolonged inventory and receivables periods imply ongoing constraints in asset management and liquidity conversion.
Turnover Ratios
Average No. Days
Inventory Turnover
DexCom Inc., inventory turnover calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Cost of sales | 351,700) | 324,900) | 278,900) | 273,900) | 275,400) | 246,700) | 230,700) | 225,600) | 203,300) | 178,000) | 161,100) | 169,800) | 160,500) | 167,700) | 148,600) | 153,500) | 149,400) | 129,900) | 111,700) | ||||||
| Inventory | 498,600) | 421,100) | 366,000) | 306,700) | 311,000) | 339,500) | 342,200) | 357,300) | 351,300) | 319,300) | 289,700) | 234,700) | 200,700) | 165,300) | 141,900) | 119,800) | 120,400) | 117,900) | 101,100) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Inventory turnover1 | 2.47 | 2.74 | 2.94 | 3.35 | 3.15 | 2.67 | 2.45 | 2.15 | 2.03 | 2.10 | 2.28 | 2.76 | 3.14 | 3.75 | 4.10 | 4.55 | 4.20 | 3.86 | 4.09 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | 2.71 | 2.62 | 2.77 | 3.10 | 3.37 | 3.24 | 3.36 | 3.59 | 3.47 | 3.27 | 2.99 | — | — | — | — | — | — | — | — | ||||||
| Intuitive Surgical Inc. | 1.99 | 2.21 | 2.25 | 2.27 | 2.36 | 2.62 | 2.82 | 2.98 | 2.90 | 2.84 | 2.64 | — | — | — | — | — | — | — | — | ||||||
| Medtronic PLC | 1.92 | 2.00 | 2.09 | 2.20 | 2.26 | 2.38 | 2.47 | 2.43 | 2.24 | 2.20 | 2.10 | — | — | — | — | — | — | — | — | ||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Inventory turnover
= (Cost of salesQ3 2023
+ Cost of salesQ2 2023
+ Cost of salesQ1 2023
+ Cost of salesQ4 2022)
÷ Inventory
= (351,700 + 324,900 + 278,900 + 273,900)
÷ 498,600 = 2.47
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several significant trends in cost of sales, inventory levels, and inventory turnover ratios over the period observed.
- Cost of Sales
- The cost of sales has exhibited a generally upward trajectory from March 2019 through September 2023. Beginning at approximately USD 111.7 million in early 2019, the figure steadily increased each quarter, reaching approximately USD 351.7 million by the third quarter of 2023. This represents more than a threefold increase over the period. The growth trend is relatively consistent, although some quarters show a sharper increase, notably from late 2021 through 2023, indicating rising production or procurement costs or increased sales volume.
- Inventory
- Inventory levels have also increased significantly across the same timeframe. Starting around USD 101.1 million, inventory rose steadily to reach roughly USD 498.6 million by September 2023. This is a substantial increase implying accumulation of stock or buildup in working capital tied to inventory. The inventory growth has been particularly pronounced from 2020 onward, with quarterly increases often exceeding USD 20 million. Notably, this build-up in inventory persisted even as cost of sales rose, which may indicate changes in inventory management, supply chain strategies, or anticipated demand fluctuations.
- Inventory Turnover Ratio
- The inventory turnover ratio has shown a declining trend over the course of the analyzed period. It started relatively high at 4.09 times in March 2019, fluctuated around values above 3 through early 2019, and then gradually decreased to 2.47 times by September 2023. The lowest turnover ratios appear between late 2020 and mid-2023. This downward trend suggests that inventory is being sold more slowly relative to the size of the inventory stock, potentially indicating overstocking, slower sales growth relative to inventory accumulation, or challenges in inventory management efficiency.
In summary, the financial data indicate that while the cost of sales and inventory amounts have both increased substantially over the assessed periods, the efficiency of converting inventory to sales, as reflected by the inventory turnover ratio, has progressively declined. This combination could point to operational challenges such as inventory buildup or slower inventory movement, which may impact liquidity and require closer management focus.
Receivables Turnover
DexCom Inc., receivables turnover calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Revenue | 975,000) | 871,300) | 741,500) | 815,200) | 769,600) | 696,200) | 628,800) | 698,200) | 650,200) | 595,100) | 505,000) | 568,900) | 500,900) | 451,800) | 405,100) | 462,800) | 396,300) | 336,400) | 280,500) | ||||||
| Accounts receivable, net | 785,700) | 750,600) | 636,800) | 713,300) | 564,100) | 560,800) | 544,500) | 514,300) | 529,100) | 483,500) | 443,400) | 428,500) | 370,000) | 296,500) | 300,700) | 286,300) | 234,900) | 217,300) | 204,700) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Receivables turnover1 | 4.33 | 4.26 | 4.75 | 4.08 | 4.95 | 4.77 | 4.72 | 4.76 | 4.38 | 4.49 | 4.57 | 4.50 | 4.92 | 5.79 | 5.32 | 5.16 | 5.75 | 5.62 | 5.51 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | 6.15 | 6.52 | 6.89 | 7.02 | 7.03 | 6.33 | 6.20 | 6.64 | 6.61 | 6.58 | 6.13 | — | — | — | — | — | — | — | — | ||||||
| Elevance Health Inc. | 17.93 | 18.82 | 16.53 | 18.81 | 19.51 | 18.80 | 16.67 | 20.66 | 18.93 | 18.81 | 17.39 | — | — | — | — | — | — | — | — | ||||||
| Intuitive Surgical Inc. | 7.12 | 7.37 | 6.95 | 6.60 | 7.20 | 7.11 | 6.52 | 7.30 | 7.90 | 7.38 | 6.96 | — | — | — | — | — | — | — | — | ||||||
| Medtronic PLC | 5.23 | 5.48 | 5.85 | 5.71 | 5.84 | 5.79 | 5.82 | 5.51 | 5.35 | 5.21 | 5.73 | — | — | — | — | — | — | — | — | ||||||
| UnitedHealth Group Inc. | 17.23 | 19.23 | 14.88 | 18.22 | 18.37 | 16.27 | 15.65 | 20.07 | 19.60 | 18.53 | 16.35 | — | — | — | — | — | — | — | — | ||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Receivables turnover
= (RevenueQ3 2023
+ RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022)
÷ Accounts receivable, net
= (975,000 + 871,300 + 741,500 + 815,200)
÷ 785,700 = 4.33
2 Click competitor name to see calculations.
The financial data exhibits several notable trends related to revenue, accounts receivable, and receivables turnover over the observed periods.
- Revenue Trends
- Revenue has generally shown a consistent upward trajectory from March 2019 through September 2023. Starting at approximately $280.5 million in March 2019, revenue increased steadily, peaking around $698.2 million in December 2021. Following a slight dip in March 2022 to $628.8 million, revenue resumed growth, reaching its highest point of approximately $975 million in September 2023. This pattern indicates robust revenue growth with minor fluctuations likely attributable to seasonality or market conditions.
- Accounts Receivable Trend
- Accounts receivable similarly increased over the period, rising from $204.7 million in March 2019 to $785.7 million in September 2023. While the growth in receivables largely parallels revenue growth, there are periods where receivables increased at a faster rate, notably between December 2022 and June 2023, where accounts receivable rose from $713.3 million to $636.8 million and then further to $750.6 million. This could suggest extended collection periods or increased credit sales during these intervals.
- Receivables Turnover Ratio
- The receivables turnover ratio, representing how many times accounts receivable is collected during a period, has generally declined from 5.51 in March 2019 to a low of 4.08 in December 2022. This downward trend indicates a lengthening in the time taken to collect receivables relative to sales. A minor recovery is observed afterward with ratios fluctuating around 4.3 to 4.75 during 2023 but remaining below earlier levels. The decline in turnover ratio, alongside rising accounts receivable, points to potential cash collection challenges or relaxed credit terms.
In summary, while the company demonstrated solid revenue growth over the analyzed periods, the accounts receivable growth outpaced revenue increases in certain intervals, and the receipt of payments slowed somewhat, as evidenced by the decreasing receivables turnover ratio. Monitoring and managing receivables efficiency may be important to sustain liquidity and operational effectiveness.
Working Capital Turnover
DexCom Inc., working capital turnover calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Current assets | 4,698,400) | 5,002,900) | 3,767,400) | 3,668,800) | 3,398,500) | 3,808,700) | 3,746,600) | 3,684,400) | 3,656,200) | 3,474,200) | 3,445,100) | 3,424,800) | 3,237,100) | 3,033,000) | 1,995,700) | 1,969,400) | 1,815,700) | 1,744,200) | 1,690,800) | ||||||
| Less: Current liabilities | 1,678,600) | 2,069,700) | 1,865,000) | 1,839,300) | 900,500) | 807,000) | 711,400) | 720,800) | 734,900) | 600,700) | 604,100) | 614,100) | 506,400) | 400,100) | 342,800) | 360,200) | 322,400) | 288,200) | 235,400) | ||||||
| Working capital | 3,019,800) | 2,933,200) | 1,902,400) | 1,829,500) | 2,498,000) | 3,001,700) | 3,035,200) | 2,963,600) | 2,921,300) | 2,873,500) | 2,841,000) | 2,810,700) | 2,730,700) | 2,632,900) | 1,652,900) | 1,609,200) | 1,493,300) | 1,456,000) | 1,455,400) | ||||||
| Revenue | 975,000) | 871,300) | 741,500) | 815,200) | 769,600) | 696,200) | 628,800) | 698,200) | 650,200) | 595,100) | 505,000) | 568,900) | 500,900) | 451,800) | 405,100) | 462,800) | 396,300) | 336,400) | 280,500) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Working capital turnover1 | 1.13 | 1.09 | 1.59 | 1.59 | 1.12 | 0.89 | 0.85 | 0.83 | 0.79 | 0.76 | 0.71 | 0.69 | 0.67 | 0.65 | 0.97 | 0.92 | 0.90 | 0.84 | 0.77 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | 4.15 | 4.39 | 4.21 | 4.48 | 3.92 | 3.63 | 4.13 | 3.87 | 3.98 | 4.02 | 3.99 | — | — | — | — | — | — | — | — | ||||||
| Elevance Health Inc. | 7.92 | 7.69 | 7.60 | 8.37 | 9.11 | 8.85 | 8.65 | 7.23 | 6.79 | 6.67 | 5.38 | — | — | — | — | — | — | — | — | ||||||
| Intuitive Surgical Inc. | 0.95 | 1.03 | 1.15 | 1.29 | 1.21 | 1.17 | 1.26 | 1.22 | 1.17 | 1.03 | 0.88 | — | — | — | — | — | — | — | — | ||||||
| Medtronic PLC | 2.81 | 2.82 | 3.84 | 2.97 | 2.21 | 2.13 | 2.15 | 2.15 | 2.02 | 2.00 | 2.44 | — | — | — | — | — | — | — | — | ||||||
| UnitedHealth Group Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Working capital turnover
= (RevenueQ3 2023
+ RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022)
÷ Working capital
= (975,000 + 871,300 + 741,500 + 815,200)
÷ 3,019,800 = 1.13
2 Click competitor name to see calculations.
The analysis of the quarterly financial metrics reveals several notable trends and patterns over the observed periods.
- Working Capital
- Working capital exhibited an overall upward trajectory from early 2019 through the end of 2021, with a steady increase from approximately 1,455,400 thousand USD in March 2019 to nearly 2,963,600 thousand USD in December 2021. This growth indicates an expansion in liquidity and short-term financial health during this period.
- In the first half of 2022, working capital remained relatively stable, fluctuating slightly between approximately 3,035,200 thousand USD and 3,001,700 thousand USD. However, a significant decline was observed in late 2022 and early 2023, with working capital dropping sharply to around 1,829,500 thousand USD by December 2022. Subsequently, it recovered again, rising back over 3,000,000 thousand USD by mid-2023.
- Revenue
- Revenue followed a generally positive growth trend over the analyzed quarters. It started at 280,500 thousand USD in March 2019 and increased consistently through 2020 and 2021, reaching 698,200 thousand USD by December 2021. Thereafter, the revenue maintained its upward momentum with some fluctuations, peaking at 975,000 thousand USD in September 2023, marking a strong growth trajectory.
- Despite some quarterly variances, revenue increases outpaced the growth in working capital for much of the examined timeline, suggesting improving operational efficiency.
- Working Capital Turnover
- The working capital turnover ratio, which indicates how efficiently working capital is used to generate revenue, initially increased from 0.77 in March 2019 to 0.97 by March 2020, reflecting improving efficiency.
- There was a notable dip during the middle of 2020, with the ratio dropping to a low of approximately 0.65 in June 2020, coinciding with a sharp increase in working capital without an immediate corresponding rise in revenue. Following this, the ratio gradually improved through 2021 and early 2022, reaching 0.89 by September 2022.
- A pronounced spike in working capital turnover occurred in late 2022 and early 2023, with the ratio surging to 1.59 in both December 2022 and March 2023. This correlates with the sharp contraction in working capital combined with relatively high revenue figures, indicating more effective utilization of working capital in generating sales.
- After this peak, turnover decreased to around 1.09-1.13 across the subsequent quarters of 2023, suggesting a normalization of working capital usage efficiency.
In summary, the company's financials illustrate a robust increase in revenue over the period, accompanied by considerable fluctuations in working capital levels. Efficiency in working capital utilization, as reflected in the turnover ratio, improved overall but showed significant short-term volatility linked to sharp changes in working capital management. The recent recovery in working capital alongside sustained revenue growth points to potential strengthening of liquidity and operational effectiveness moving into mid-2023.
Average Inventory Processing Period
DexCom Inc., average inventory processing period calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Inventory turnover | 2.47 | 2.74 | 2.94 | 3.35 | 3.15 | 2.67 | 2.45 | 2.15 | 2.03 | 2.10 | 2.28 | 2.76 | 3.14 | 3.75 | 4.10 | 4.55 | 4.20 | 3.86 | 4.09 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average inventory processing period1 | 148 | 133 | 124 | 109 | 116 | 137 | 149 | 170 | 180 | 174 | 160 | 132 | 116 | 97 | 89 | 80 | 87 | 95 | 89 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | 135 | 139 | 132 | 118 | 108 | 113 | 109 | 102 | 105 | 111 | 122 | — | — | — | — | — | — | — | — | ||||||
| Intuitive Surgical Inc. | 183 | 166 | 162 | 161 | 155 | 139 | 130 | 122 | 126 | 129 | 138 | — | — | — | — | — | — | — | — | ||||||
| Medtronic PLC | 190 | 183 | 174 | 166 | 161 | 153 | 148 | 150 | 163 | 166 | 174 | — | — | — | — | — | — | — | — | ||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 2.47 = 148
2 Click competitor name to see calculations.
- Inventory Turnover Ratio
- The inventory turnover ratio demonstrates a declining trend from March 2019 through mid-2021. Initially, the ratio was above 4.0, indicating efficient inventory management. However, it progressively decreased, reaching its lowest point in June 2021 at approximately 2.1. Following this period, the ratio showed a gradual recovery into late 2022, peaking around 3.35 in December 2022. Despite this rebound, there is a slight decline observed again by the third quarter of 2023, with the ratio dropping to 2.47.
- Average Inventory Processing Period
- The average inventory processing period exhibits a roughly inverse pattern to the inventory turnover. Starting at around 89 days in March 2019, it generally increased over time, peaking at 180 days in September 2021. This extended period indicates slower inventory movement during this timeframe. From this peak, the duration began to decrease, reaching a low of approximately 109 days in December 2022, which implies improved inventory handling efficiency. However, similar to the turnover ratio, the period starts to lengthen again after this point, rising to about 148 days by September 2023.
- Overall Insights
- The data suggests a period of declining inventory management efficiency from 2019 to mid-2021, as evidenced by falling turnover ratios and increasing processing periods. The company then appears to have taken measures that enhanced inventory turnover and reduced processing times through late 2022. Nevertheless, the trends toward the end of the analyzed period point to a renewed slowdown in inventory movement, implying potential challenges in inventory management or shifts in demand patterns during 2023.
Average Receivable Collection Period
DexCom Inc., average receivable collection period calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Receivables turnover | 4.33 | 4.26 | 4.75 | 4.08 | 4.95 | 4.77 | 4.72 | 4.76 | 4.38 | 4.49 | 4.57 | 4.50 | 4.92 | 5.79 | 5.32 | 5.16 | 5.75 | 5.62 | 5.51 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average receivable collection period1 | 84 | 86 | 77 | 89 | 74 | 77 | 77 | 77 | 83 | 81 | 80 | 81 | 74 | 63 | 69 | 71 | 63 | 65 | 66 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | 59 | 56 | 53 | 52 | 52 | 58 | 59 | 55 | 55 | 55 | 60 | — | — | — | — | — | — | — | — | ||||||
| Elevance Health Inc. | 20 | 19 | 22 | 19 | 19 | 19 | 22 | 18 | 19 | 19 | 21 | — | — | — | — | — | — | — | — | ||||||
| Intuitive Surgical Inc. | 51 | 50 | 53 | 55 | 51 | 51 | 56 | 50 | 46 | 49 | 52 | — | — | — | — | — | — | — | — | ||||||
| Medtronic PLC | 70 | 67 | 62 | 64 | 63 | 63 | 63 | 66 | 68 | 70 | 64 | — | — | — | — | — | — | — | — | ||||||
| UnitedHealth Group Inc. | 21 | 19 | 25 | 20 | 20 | 22 | 23 | 18 | 19 | 20 | 22 | — | — | — | — | — | — | — | — | ||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 4.33 = 84
2 Click competitor name to see calculations.
The analysis of the receivables turnover ratio and the average receivable collection period over the quarterly periods reveals notable fluctuations and trends in the company's credit management and cash collection efficiency.
- Receivables Turnover Ratio
- The receivables turnover ratio exhibits a general decline over the observed period. Starting from a high of 5.75 in September 2019, the ratio gradually decreases, hitting lower points around 4.08 in December 2022. Although occasional recoveries occur, such as a rise to 4.95 in September 2022 and 4.75 in March 2023, the overall trend indicates diminishing efficiency in collecting receivables. This decline suggests that the company may be taking longer to collect its outstanding receivables or experiencing challenges in managing credit sales.
- Average Receivable Collection Period
- The average collection period, which inversely correlates with the receivables turnover ratio, shows a general upward trend, indicating elongation in the time taken to collect receivables. Initially, the collection period was relatively low at 63 days in September 2019 but increased to a peak of 89 days by December 2022. Although there are some fluctuations with periods of slight decreases (e.g., a drop to 74 days in September 2022 following higher values), the overall pattern points toward slower collection cycles, potentially impacting cash flows.
- Relationship and Implications
- The inverse relationship between the receivables turnover ratio and the average collection period throughout the timeline confirms typical financial behavior in credit management. The trend of decreasing turnover ratios combined with increasing collection periods suggests potential issues in receivables management, such as extended credit terms or inefficiencies in collections. Such developments might necessitate internal reviews to enhance credit policies, improve customer payment terms, or strengthen follow-up processes to optimize working capital.
Operating Cycle
DexCom Inc., operating cycle calculation (quarterly data)
No. days
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Average inventory processing period | 148 | 133 | 124 | 109 | 116 | 137 | 149 | 170 | 180 | 174 | 160 | 132 | 116 | 97 | 89 | 80 | 87 | 95 | 89 | ||||||
| Average receivable collection period | 84 | 86 | 77 | 89 | 74 | 77 | 77 | 77 | 83 | 81 | 80 | 81 | 74 | 63 | 69 | 71 | 63 | 65 | 66 | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Operating cycle1 | 232 | 219 | 201 | 198 | 190 | 214 | 226 | 247 | 263 | 255 | 240 | 213 | 190 | 160 | 158 | 151 | 150 | 160 | 155 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Operating Cycle, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | 194 | 195 | 185 | 170 | 160 | 171 | 168 | 157 | 160 | 166 | 182 | — | — | — | — | — | — | — | — | ||||||
| Intuitive Surgical Inc. | 234 | 216 | 215 | 216 | 206 | 190 | 186 | 172 | 172 | 178 | 190 | — | — | — | — | — | — | — | — | ||||||
| Medtronic PLC | 260 | 250 | 236 | 230 | 224 | 216 | 211 | 216 | 231 | 236 | 238 | — | — | — | — | — | — | — | — | ||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 148 + 84 = 232
2 Click competitor name to see calculations.
The analysis of the financial data reveals several noteworthy trends over the examined periods regarding the company's inventory management, receivable collection efficiency, and overall operating cycle.
- Average Inventory Processing Period
- The inventory processing period exhibits a generally increasing trend from the first quarter of 2019 to the third quarter of 2023. Starting at 89 days in March 2019, it fluctuates slightly in the initial periods but rises steadily from mid-2020 onwards, peaking between 160 and 180 days during 2021. A subsequent moderate decline occurs through 2022, reducing the period to approximately 109 days by December 2022. However, the trend reverses again in 2023, with the period extending to 148 days by September 2023. This pattern indicates a growing duration for inventory turnover, with intermittent improvements, suggesting potential challenges in inventory management or changes in product demand and supply chain dynamics.
- Average Receivable Collection Period
- The receivable collection period remains relatively stable over the timeframe, hovering generally between 63 and 89 days. Initial periods show minor fluctuations, with a slight decrease in mid-2019 followed by an increase in late 2019 and 2020. The period largely stays within the 70-80 day range through 2021 and 2022, with a noticeable peak reaching 89 days in June 2023. This consistency suggests steady credit management practices, although recent increases could imply emerging difficulty in collections or extended credit terms offered to customers.
- Operating Cycle
- The operating cycle, which combines inventory processing and receivable collection periods, also reveals a rising trend over the period analyzed. Starting near 155 days in early 2019, it gradually lengthens to approximately 263 days by the latter part of 2021, indicating an elongation of the company's cash-to-cash cycle. A reduction is observed in 2022, with the cycle decreasing to around 190 days by year-end, followed by a new upward movement reaching 232 days by September 2023. These shifts reflect the combined effects of inventory and receivable period changes and suggest variabilities in working capital efficiency.
Overall, the extended inventory processing times and the stable yet slightly increasing receivable collection periods contribute to a lengthening operating cycle. This pattern may indicate periods of lower operational efficiency or strategic adjustments in working capital management that could impact cash flow and liquidity. Continuous monitoring and targeted actions to optimize inventory turnover and receivables collection may be necessary to improve operational performance.